Growth hormone receptor (GHR) is a member of the cytokine/hematopoietin receptor superfamily. Once the ligand growth hormone (GH) binds GHR, two GHRs are dimerized by a single GH molecule, which results in the recruitment and binding of JAK2 tyrosine kinase and the activation of intracellular signal transduction pathways.
It was reported that ligand-induced rabbit GHR internalization and degradation in transfected CHO cells was dependent on the ubiquitin conjugation system. 7) Moreover, proteasome inhibitors have been shown to inhibit GH-induced endocytosis. 8) However, it has been shown that ubiquitination of the GHR itself is not necessary for ligand-induced internalization. 9) Thus, the role of ubiquitination and the proteasome system in ligand-induced GHR endocytosis is still obscure. Furthermore, there is no report on the role of proteasomes in the constitutive internalization and degradation of hGHRs.
In this report, in order to clarify the mechanisms of the constitutive degradation of GHR, we investigated the effects of the proteasome inhibitors on the degradation of hGHR in hGHR-transfected murine Ba/F3 (Ba/F3-hGHR) cells.
MATERIALS AND METHODS
Reagents and Cell Line MG-132, clasto-lactacystin blactone and immobilized anti-mouse Ig were obtained from Calbiochem (La Jolla, CA, U.S.A.). Cycloheximide (CHX), aprotinin, leupeptin, trypsin, and trypsin inhibitor were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). N-ethylmaleimide and bafilomycin A 1 were obtained from Wako (Osaka, Japan). The 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (Pefabloc SC) was from Merck (Darmstadt, Germany). Pepstatin A was purchased from Chemicon International, Inc. (Temecula, CA, U.S.A.). RPMI 1640 medium was purchased from Life Technology (Grand Island, NY, U.S.A.). G418 was from Promega Corporation (Madison, WI, U.S.A.). Anti-rat GHR monoclonal antibody 263 (mAb 263, IgG 1 subtype) was obtained from Agen Biomedical (Queensland, Australia) and the ascites of monoclonal anti-human GHR antibody GHRP2-88 (IgG 2a ) was prepared as described previously. 10) Rabbit anti-ubiquitin polyclonal antibodies, U5379 and SPA-200 were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.) and Stress Gen Biotechnologies Corp. (Victoria, Canada), respectively. Recombinant hGH (methionyl hGH) was kindly provided by Sumitomo Pharmaceutical Co. (Osaka, Japan) and radiolabeled with 125 I-NaI (NEN Life Science Products, Inc., Boston, MA, U.S.A.) by the chloramine-T method.
11) The specific activity of 125 I-hGH ranged from 3-4 MBq/mg. Ba/F3-hGHR cells were kindly provided by Mitsui Chemicals, Inc. Full-length hGHR cDNA was transfected into the mouse pro-B cell line Ba/F3 cells by electroporation, and the cells stably expressing hGHR were established.
12) The cells were cultured in RPMI 1640 medium containing 1 mg/ml G418, 10% FCS, 50 mM 2-mercaptoethanol, 10% of a WEHI-3 cell culture supernatant as a source of interleukin-3 (IL-3) or 1.5 ng/ml recombinant mouse IL-3 (Pepro Tech EC, London, U.K.), and 60 mg/ml kanamycin.
Immunoblotting of hGHRs and hGH-BPs Immunoblotting of hGHRs in the cell lysate and hGH-BPs in the culture medium using the GHRP2-88 antibody and 125 I-la-
In the mouse Ba/F3-hGHR cell line, which stably expresses human growth hormone receptors (hGHRs), the hGHRs were rapidly degraded in the absence of the ligand. Human growth hormone-binding protein (hGH-BP), a soluble form of hGHR, was released from Ba/F3-hGHR cells, but the hGH-BP release was less than 1% of total hGHRs in the cells. Therefore, the hGH-BP release does not markedly contribute to hGHR degradation in Ba/F3-hGHR cells.
The Ubiquitinated hGHRs were detected in the cell lysate and increased by hGH-treatment. Furthermore, MG-132 accumulated the ubiquitinated hGHRs induced by hGH. However, the ratio of ubiquitinated hGHRs to unubiquitinated hGHRs was very small, even with treatment involving both hGH and MG-132. In the hGH-untreated cells, the ubiquitinated hGHRs were weakly detected. However, the ubiquitination of hGHR was not enhanced by MG-132 as a result of immunoblotting. Thus, the ubiquitination of hGHR is unlikely to be involved, at least in the constitutive degradation.
Taken together, both the proteasome pathway and endosome/lysosome pathway are involved in the constitutive degradation of hGHRs. Our results also suggest that ubiquitination of the hGHR itself is unlikely to be the trigger of the proteasome-dependent degradation.
belled anti-mouse Ig [F(abЈ) 2 fragment] was performed as described previously.
10) The intensity of the bands was determined with BAS 1500 (Fuji Film, Tokyo, Japan).
Determination of Cell Surface hGHR Levels by 125 IhGH Binding Assay Ba/F3-hGHR cells were suspended in RPMI 1640 medium containing 5% FCS at 1ϫ10 6 cells/ml and preincubated at 37°C for 16 h. After MG-132 (50 mM) was added, cells were reincubated for 30 min followed by the addition of CHX (50 mM), and they were further incubated for the indicated periods of time. After incubation, the cells were washed twice with 10 mM Tris-buffered saline (pH 7.4) containing 0.1% BSA (TBS-BSA), resuspended in TBS-BSA and divided into 3 tubes (7ϫ10 6 cells/0.5 ml/tube). 125 IhGH was added into the tubes (8ϫ10 5 cpm/tubes), which were then incubated at 4°C for 2 h. Then the cells were washed twice with TBS-BSA, and the bound 125 I-hGH was determined using a g-counter.
Immunoprecipitation and Immunoblotting of Ubiquitinated hGHRs Ba/F3-hGHR cells were suspended in RPMI 1640 medium containing 10% FCS at 4ϫ10 6 cells/ml and preincubated for 15 min at 37°C. MG-132 (50 mM) or vehicle (DMSO) was added to the cells, and they were reincubated for 30 min at 37°C. The cells were further incubated with or without 45 nM hGH for 30 min at 37°C. At the end of the incubation, an equal volume of ice-cold stop buffer [20 mM Tris-HCl (pH 7.4) containing 10 mM EDTA, 100 mM NaF, 60 mM Na 4 P 2 O 7 , 4 mM Na 3 VO 4 , 5 mM N-ethylmaleimide, 20 mM leupeptin, 20 mM pepstatin A, and 1 mM PMSF] was added, and the cells were immediately centrifuged at 200ϫg for 5 min at 4°C. The cells were washed with Buffer A [20 mM Tris-HCl (pH 7.4) containing 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 30 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 5 mM N-ethylmaleimide, 10 mM MG-132, 20 mM leupeptin, 20 mM pepstatin A, 1 mM Pefabloc SC, and 10 mg/ml aprotinin]. The precipitated cells were resuspended in Buffer A containing 2% Nonidet P-40 (NP-40), solubilized at 4°C for 60 min using a rotating cultivator and centrifuged at 12000ϫg for 20 min at 4°C. The supernatants were mixed with Buffer A to reduce the NP-40 concentration to 0.5%, precleared with anti-mouse Ig beads for 2 h at 4°C, incubated with anti-GHR monoclonal antibody mAb263 (20 mg/ml) for 30 min at 4°C, and then with anti-mouse Ig beads for 16 h at 4°C. The beads were washed five times with Buffer A containing 0.5% NP-40, and the bound proteins were released by boiling the beads in Laemmli buffer, followed by SDS-PAGE (4% gel). Electrophoresed proteins were transferred to polyvinylidene difluoride membranes at 60 mA (25 V) for 16 h at 4°C. The membranes were blocked with 0.5% casein-PBS (pH 7.4) for 2.5 h at room temperature and then treated with a combination of rabbit anti-ubiquitin antibodies (U5379 and SPA200) or mouse anti-GHR monoclonal antibody GHRP2-88 for 2 h at room temperature. After being washed four times with 0.05% Tween-PBS (pH 7.4) for 10 min, the membranes were treated with [
125 I] anti-rabbit or mouse Ig [F(abЈ) 2 fragment, 1ϫ10 6 cpm] for 60 min at 37°C, washed, and subjected to analysis with BAS1500 (Fuji Film, Tokyo, Japan).
RESULTS

Human GHR Degradation in the Ba/F3-hGHR Cells
We chose hGHR-transfected Ba/F3 cells since endogenous murine GHRs were negligible. 13) During the experiments, hGHR levels were constant in untreated cells (data not shown). When 50 mM cycloheximide (CHX) was added to the Ba/F3-hGHR cells to inhibit de novo hGHR synthesis, the hGHR level was rapidly reduced (Fig. 1) . The half-time for The cells were suspended in RPMI 1640 medium containing 5% FCS at 1ϫ10 6 cells/ml and dispensed into 25 cm 2 tissue culture flasks (5ϫ10 6 cells/5 ml/ flask). They were preincubated at 37°C for 16 h to stabilize the hGHR level. Immediately after CHX (50 mM) and/or MG-132 (50 mM) were added to the flasks, they were reincubated for the indicated periods of time. When the ligand-induced degradation was examined, hGH (45 nM) was added to the cells 30 min after the addition of CHX and/or MG-132. The cell lysates (from 1ϫ10 6 cells) were subjected to SDS-PAGE, followed by immunoblotting using the anti-hGHR antibody, 2-88. The intensity of bands corresponding to hGHR (A) was assessed with BAS 1500 and plotted. The results in panel (B) are the meanϮS.D. of 3-5 independent experiments. the reduction in the hGHR band intensity was estimated to be ca. 100 min (Fig. 1B) . Thus, hGHRs were rapidly degraded in Ba/F3-hGHR cells. Similar results were obtained for the GHR turnover rates of cultured mouse cells (BALB/c 3T3; 1.25 h), 14) and cultured rat adipocytes (45 min). 15) We have previously described that the proteolytic cleavage of the extracellular domain of GHR at the cell surface results in the release of soluble growth hormone-binding protein (GH-BP) from IM-9 cells, 16) which is one of the mechanisms of hGHR degradation. Ba/F3-hGHR cells also constitutively released hGH-BPs, but the amount was very little. Figure 2 shows immunoblotting of hGHRs in the whole cell lysate (1ϫ10 6 cells/lane) and of hGH-BPs in the culture medium (2ϫ10 7 cells/lane) after 1 h of incubation. The released hGHBPs were less than 1% of total hGHRs, as assessed by their band intensities. Therefore, it is suggested that the hGH-BP release does not markedly contribute to hGHR degradation in Ba/F3-hGHR cells, and that hGHRs were degraded within the cells but not on the cell surfaces.
Effect of Proteasome Inhibitors on the hGHR Degradation We next used a proteasome inhibitor, MG-132, in order to clarify the possibility of proteasome involvement in the constitutive degradation of hGHR. MG-132 completely inhibited the degradation of hGHR in the presence of CHX. Moreover, hGHR levels were increased by the addition of MG-132 in the absence of CHX (Fig. 1) .
Addition of the ligand, hGH (45 nM), caused an accelerative reduction in hGHR levels in the presence of CHX, and the addition of MG-132 completely blocked the degradation, even in the presence of hGH. Stimulation by hGH without CHX increased hGHR levels (data not shown). These results suggest that proteasomes are likely to be involved both in the constitutive and ligand-induced degradation of hGHRs.
To confirm the involvement of proteasomes, another inhibitor was tested for the inhibition of constitutive hGHR degradation in the presence of CHX. Like MG-132, an active analog of lactacystin, clasto-lactacystin b-lactone 17) inhibited the degradation (Fig. 3A, lanes 1 and 2) . Protease inhibitors, Pefabloc SC, leupeptin and pepstatin A, did not affect the constitutive degradation of hGHR (Fig. 3A, lanes 4-6) . Besides the proteasome inhibitors, a specific inhibitor of vacuolar H ϩ -ATPase, bafilomycin A1, 18) also inhibited hGHR degradation (Fig. 3A, lane 3) , suggesting the involvement of the endosome/lysosome system in the degradation pathway. MG-132, clasto-lactacystin b-lactone and bafilomycin A 1 increased the hGHR levels under the condition without CHX (Figs. 1 and 3B) .
Effect of MG-132 on the Internalized and Cell Surface hGHRs Next, we tried to reveal the site of the hGHR-endocytosis pathway influenced by MG-132. First, we used trypsin treatment to remove cell surface hGHRs, which revealed that about 30% of total hGHRs was localized in intracellular organs, and these intracellular hGHRs almost disappeared by CHX addition (Fig. 4) . This finding indicates that newly synthesized intracellular mature hGHRs on the way to the cell surface were about one-third of whole cell hGHRs. MG-132 partially restored the intracellular hGHRs, even in the presence of CHX, suggesting that the degradation of internalized hGHRs were inhibited by MG-132. Without CHX, intracellular hGHRs accumulated by the addition of MG-132. The cell surface hGHR level, determined by 125 I-hGHbinding assay, was also reduced by CHX addition (Fig. 5 ), but the reduction was slow as compared with that obtained for whole cell lysates (Fig. 1) . Thus, the decrease in hGHRs by CHX in Fig. 1 mostly reflects the loss of intracellular hGHRs shown in Fig. 4 . Accumulation of cell surface hGHRs and the inhibition of CHX-induced reduction in cell surface hGHRs were also significantly seen in the presence of MG-132, suggesting that MG-132 also inhibits the internalization of hGHRs from the cell surface.
Detection of Ubiquitinated hGHRs Since the proteasome function is shown to be linked with both constitutive and ligand-enhanced degradation of hGHRs in the present study, we then attempted to detect the ubiquitination of hGHRs in order to assess its involvement in the constitutive degradation of hGHRs. At first, we confirmed that the combination of the two antibodies we used was capable of detect- The cells were suspended in FCS-Free-RPMI 1640 medium at 4ϫ10 6 cells/ml and incubated for 1h at 37°C. The cell lysates (from 1ϫ10 6 cells/lane) and the concentrated supernatants (from 2ϫ10 7 cells/lane) were subjected to SDS-PAGE, followed by immunoblotting in the same manner as in Fig. 1 . cells, B) were subjected to SDS-PAGE, followed by immunoblotting using anti-hGHR antibody, 2-88. Control, treated with 50 mM CHX; inhibitor 1, 50 mM MG-132; 2, 20 mM clasto-lactacystin b-lactone; 3, 1 mM bafilomycin A 1 ; 4, 500 mM Pefabloc SC; 5, 100 mM leupeptin; 6, 100 mM pepstatin A.
Fig. 4. Effect of CHX and/or MG-132 on the Whole and Intracellular hGHR Levels
Ba/F3-hGHR cells (4ϫ10 6 /ml) were incubated with CHX and/or MG-132 for 90 min at 37°C and treated or untreated with 100 mg/ml trypsin for 5 min at 37°C. After the proteolytic reaction was stopped by adding leupeptin (20 mM) and trypsin inhibitor (100 mg/ml), the cells were washed and the whole cell lysates were subjected to SDS-PAGE, followed by immunoblotting using the anti-hGHR monoclonal antibody 2-88.
ing ubiquitinated proteins in immunoblotting (Fig. 6A) . In the MG-132-treated cell lysates, ubiquitinated proteins were more strongly stained than those in untreated cells, indicating that the combined antibodies were able to detect the ubiquitinated proteins accumulated by MG-132. Using these combined antibodies, we next tried to detect the ubiquitinated GHR.
As shown in Fig. 6B , broad bands with high molecular weights were immunostained with the combined anti-ubiquitin antibodies in the hGHR-immunoprecipitated fractions, and these broad bands were also detected by staining with an anti-hGHR antibody against the extracellular region of the receptor, as indicated in Fig. 6D . Moreover, the intensities of the broad bands in each treatment were correlative between these experiments. Therefore, the bands were suggested to correspond to ubiquitinated hGHRs. Ubiquitinated hGHRs were increased by hGH-treatment, and the intensities of the bands were enhanced by further treatment of MG-132 (Figs. 6B and D) . However, when the sensitivity was adjusted to unconjugated hGHRs, the ubiquitinated hGHR band was very slight (Fig. 6C) , and a 6-fold amount of immunoprecipitates was used for the anti-ubiquitin immunoblotting (Fig. 6B) , compared with the anti-hGHR immunoblotting (Fig. 6D) . Thus, the amount of ubiquitinated hGHR appeared to be very small compared with that of the unconjugated receptors, even with treatment using both hGH and MG-132.
In the hGH-untreated cells, the ubiquitinated hGHRs were weakly detected (Figs. 6B and D) . However, the presence of MG-132 did not affect the level of ubiquitinated hGHRs in the absence of hGH. From these data, it is unlikely that the ubiquitination of hGHRs is involved, at least in the constitutive degradation of hGHRs.
DISCUSSION
In the present study, we showed that the constitutive and ligand-enhanced degradation of hGHRs was inhibited by the proteasome inhibitor MG-132. Our data suggest that the hGHR degradation is linked with the proteasome pathway. It is likely that GHRs are degraded by similar mechanisms irrespective of the presence of the ligand, and that the ligand may just accelerate the degradation.
So far, many receptors on plasma membranes have been found to be ubiquitinated in response to ligand binding; for example, yeast a-factor receptor, 19) epidermal growth factor (EGF) receptor, 20) platelet-derived growth factor (PDGF) receptor, 21) T cell antigen receptor z subunit 22) and the c-kit receptor. 23, 24) It is speculated that ubiquitination of the receptors is a trigger for internalization and degradation in the endosome/lysosome system. 25) However, the site where the proteasome acts in the endocytic pathway and its mechanism of action are still unclear.
Detection of ubiquitinated proteins by immunoblotting is rather difficult because of the low electrophoretic transfer efficiency of high molecular weight ubiquitinated proteins to the membrane and deubiquitination during sample preparation caused by ubiquitin C-terminal hydrolases in the cell lysate, 26) which can release ubiquitin molecules from ubiqui- Ba/F3-hGHR cells were preincubated in RPMI 1640 medium containing 10% FCS (1ϫ10 6 cells/ml) at 37°C for 16 h, reincubated in the presence or absence of MG-132 (50 mM) for 30 min, and further incubated with or without CHX (50 mM) for the indicated periods of time. hGHR levels on the cell surface were determined by a binding assay using tin-conjugated proteins. It is possible that hydrolysis regenerates intact hGHRs from ubiquitinated hGHRs during the immunoprecipitation process. Therefore, we used a sulfhydryl blocking agent, N-ethylmaleimide, to minimize deubiquitination by isopeptidase T and the proteasome inhibitor, MG-132, to inhibit proteasome activity during the immunoprecipitation process. We also transferred the ubiquitinated proteins to the membrane at twice as high an electric current as used for the transfer of hGHRs. Under the conditions we used, ubiquitinated hGHRs were detected and hGH strongly increased their intensity. Furthermore, the ubiquitinated hGHRs were accumulated by the co-existence of MG-132 (Figs. 6B and D) .
It is reported that hGH-induced dimerization of hGHRs caused internalization, and that the internalized receptors were degraded in lysosomes. 15, [27] [28] [29] Govers et al., 9) using a mutant GHR in which all cytoplasmic lysine residues were mutated to arginine, demonstrated that the conjugation of ubiquitin to a lysine residue in the intracellular domain of GHR was not necessary for the ligand-induced internalization. Our results also support this idea. The ratio of ubiquitinated hGHRs to the unubiquitinated ones was very small, even in MG-132/hGH-treated cells ( Fig. 6C and D ), in contrast to the complete restoration by MG-132 from hGH-induced 70% loss of hGHR in the presence of CHX (Fig. 1) .
In the absence of ligands, receptor dimerization and subsequent internalization could not occur. Also, the intensities of the bands of ubiquitinated hGHRs were weak and not enhanced by additional treatment with MG-132 (Figs. 6B and  D) . Thus, it is unlikely that ubiquitination of hGHRs is involved in the constitutive degradation of hGHRs.
The inhibition of constitutive degradation by bafilomycin A 1 and MG-132 suggested that both proteasomes and lysosomes were involved in the degradation of hGHRs. MG-132 inhibited both the internalization and degradation of hGHRs in the absence of ligands. Therefore, proteasomes may be involved in the different phases of hGHR internalization/degradation pathways. The mechanisms of proteasome action in the degradation system are yet to be determined.
Taken together, our data suggest that hGHRs are constitutively degraded through a proteasome-dependent pathway in Ba/F3-hGHR cells; however, this is likely to be independent of the ubiquitination of hGHR itself.
